NRx Pharmaceuticals, Inc.
NASDAQ:NRXPBiotechnology
+$0.06 today
- Market cap
- $124.12M
- Beta
- 2.19
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$0.76
Volume 2.09M
Average 1.27M
NRXP Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
NRx Pharmaceuticals, Inc.NASDAQ: NRXP
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables remains negative
Q1 FY2026 net receivables was $181K, compared with $0 a year earlier. Over 3 fiscal years it compounded at +184.4% a year.
Context
- Net receivables amounted to 1.5% of total assets at the end of Q1 FY2026, up 1.5 pp from a year earlier.
- Net receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 161K USD
- Year-over-year change
- —
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 161K | — |
| FY2024 | 2024-12-31 | 0 | -100.0% |
| FY2023 | 2023-12-31 | 6K | -14.3% |
| FY2022 | 2022-12-31 | 7K | — |
| FY2021 | 2021-12-31 | 0 | — |
Net Receivables vs competitors
How NRXP compares with its peers on the latest reported figures
- NRXP's Mar 2026 net receivables of $181K is the 4th highest of the 9 companies compared; the peer median is $7.64K.
- Net receivables amounts to 1.5% of total assets for NRXP, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $23.36M | -33.7% | -17.8% | 17.8% | |
| Mar 2026 | $5.35M | — | +407.4% | 17.3% | |
| Mar 2026 | $2.72M | — | — | 12.4% | |
| Mar 2026 | $181K | — | +184.4% | 1.5% | |
| Mar 2026 | $15.29K | — | -3.1% | 0.1% | |
| Mar 2026 | $0 | -100.0% | -5.1% | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | -100.0% | -70.3% | 0.0% | |
| Jun 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding NRXP) | $7.64K | -100.0% | -5.1% | 0.0% | |
Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
Intrinsic Alpha fair value
Locked
Current Price
$2.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.